8:30     Breakfast and Registration

9:00     Welcome
Suzanne Tomlinson, Gulf Coast Consortia

Session 1: Where we are now: Houston-based resources

Convener:  Suzanne Tomlinson, Gulf Coast Consortia

9:05     Current State of the Field and Opportunities for Small Molecules ADME (PK/PD) and Overview of CCPF
Dong Liang,  Texas Southern University

9:25  Current State of the Field and Opportunities for Large Molecules ADME (PK/PD) and Overview of Preclinical Development Core for Large Molecule Therapeutics
Jim Liu,  University of Texas Health Science Center

9:45     Panel Q&R Dong Liang and Jim Liu

10:00    Characterization and Formulation Considerations for Small Molecule Preclinical Drug Development
Huan Xie, Texas Southern University

10:20    Characterization and Formulation Considerations for Large Molecule Preclinical Drug Development
 Xinli Liu, UH

10:40    Panel Q&R

10:55    Break

Session 2: Where are we now: Pharma Perspective

Convener: Huan Xie, Texas Southern University

11:15   ADME Sciences: Where are we now and where do we go next?
Christopher Gibson, Merck

11:45    TBD in Pharma Drug Development
Xiuqing Gao,  Alnylam Pharmaceuticals

12:15    Panel – what is next for Pharma

12:30    Lunch

Convener: Dong Liang, Texas Southern University

1:30     Taking Toxicology Studies to the Next Level
Jeff Larson, Tvardi Therapeutics

Session 3: Where we are going

Convener: Stan Watowich, Ridgeline Therapeutics and University of Texas Medical Branch Galveston

2:00     Alternate Paradigms to Pharmaceutical Product Development
Roger Nosal, NGT BioPharma  and PharmaCMC

2:30     Predicting Oral Absorption with ADME Models & PBPK Simulations
Michael Lawless, Simulations Plus Modeling

2:50     Leveraging Chemical Foundation Models for ADMET Modeling
Bharath Ramsundar, DeepForest Sciences

3:10     Brainstorming Session: How do we take Houston to the next level?
Moderator, Stan Watowich, Ridgeline Therapeutics, and University of Texas Medical Branch Galveston

3:45     Wrap up